Head-to-head · WeighScore
GetRelief Rx vs Omada Health
The verdict
GetRelief Rx takes it — 58.9/100 to 55.6/100.
GetRelief Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Get Relief RX, LLC (getreliefrx.com) is a Billings, Montana-based telehealth offering compounded SUBLINGUAL semaglutide (6mg, 9mg) and compounded SUBLINGUAL tirzepatide (7.5mg, 13mg, 16mg).
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | GetRelief Rx | Omada Health |
|---|---|---|
| WeighScore | 58.9/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #353 | #435 |
| Semaglutide | $269/mo (9 mg dose, compounded oral) | Not disclosed |
| Tirzepatide | $179/mo (16 mg dose, compounded oral) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #353 · C
Strengths
- Compounded semaglutide and tirzepatide priced publicly — no login required to see costs
- BBB accredited with an A rating (March 2026)
- Free online assessment with no upfront consultation fee
Where it loses points
- Sublingual drops only — no injectable; this delivery method wasn't studied in the STEP/SURMOUNT trials
- Still sells compounded tirzepatide after the FDA ended compounding enforcement discretion in 2025
- No LegitScript, PCAB, or NABP pharmacy certifications found
- Prescriber credentials listed only as 'licensed clinicians' with no detail on degree type
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.